These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 38485551)

  • 1. Targeted Agents in Esophagogastric Cancer Beyond Human Epidermal Growth Factor Receptor-2.
    Mehlhaff E; Miller D; Ebben JD; Dobrzhanskyi O; Uboha NV
    Hematol Oncol Clin North Am; 2024 Jun; 38(3):659-675. PubMed ID: 38485551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New therapeutic target molecules for gastric and gastroesophageal junction cancer.
    Kawakami H
    Int J Clin Oncol; 2024 Sep; 29(9):1228-1236. PubMed ID: 38630383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review.
    Chen LT; Oh DY; Ryu MH; Yeh KH; Yeo W; Carlesi R; Cheng R; Kim J; Orlando M; Kang YK
    Cancer Res Treat; 2017 Oct; 49(4):851-868. PubMed ID: 28052652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarker-driven targeted therapies for gastric/gastro-esophageal junction malignancies.
    Kim S; Barzi A; Rajdev L
    Semin Oncol; 2018 Jun; 45(3):133-150. PubMed ID: 30262395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER2 directed therapy for gastric/esophageal cancers.
    Won E; Janjigian YJ; Ilson DH
    Curr Treat Options Oncol; 2014 Sep; 15(3):395-404. PubMed ID: 24811128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole-transcriptome sequencing in advanced gastric or gastroesophageal cancer: A deep dive into its clinical potential.
    Hashimoto T; Nakamura Y; Mishima S; Nakayama I; Kotani D; Kawazoe A; Kuboki Y; Bando H; Kojima T; Iida N; Shibuki T; Imai M; Fujisawa T; Nagamine M; Sakamoto N; Kuwata T; Yoshino T; Shitara K
    Cancer Sci; 2024 May; 115(5):1622-1633. PubMed ID: 38429886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on Gastroesophageal Adenocarcinoma Targeted Therapies.
    Maron SB; Catenacci DVT
    Hematol Oncol Clin North Am; 2017 Jun; 31(3):511-527. PubMed ID: 28501091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular targeted agents for gastric and gastroesophageal junction cancer.
    Oshima T; Masuda M
    Surg Today; 2012 Apr; 42(4):313-27. PubMed ID: 22127535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress and challenges in HER2-positive gastroesophageal adenocarcinoma.
    Zhao D; Klempner SJ; Chao J
    J Hematol Oncol; 2019 May; 12(1):50. PubMed ID: 31101074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perspectives of HER2-targeting in gastric and esophageal cancer.
    Gerson JN; Skariah S; Denlinger CS; Astsaturov I
    Expert Opin Investig Drugs; 2017 May; 26(5):531-540. PubMed ID: 28387541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular-targeted first-line therapy for advanced gastric cancer.
    Song H; Zhu J; Lu D
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD011461. PubMed ID: 27432490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current and Future Biomarkers in Esophagogastric Adenocarcinoma.
    Sappenfield R; Mehlhaff E; Miller D; Ebben JE; Uboha NV
    J Gastrointest Cancer; 2024 Jun; 55(2):549-558. PubMed ID: 38280174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2 amplification status in gastric and gastro-oesophageal junction cancer in routine clinical practice: which sample should be used?
    Perrone G; Amato M; Callea M; Rabitti C; Righi D; Crucitti P; Coppola R; Onetti Muda A
    Histopathology; 2012 Jul; 61(1):134-5. PubMed ID: 22551459
    [No Abstract]   [Full Text] [Related]  

  • 14. Targeted Therapies for Advanced Oesophagogastric Cancer: Recent Progress and Future Directions.
    Young K; Chau I
    Drugs; 2016 Jan; 76(1):13-26. PubMed ID: 26620367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the HER2 pathway for the therapy of lower esophageal and gastric adenocarcinoma.
    Kaur A; Dasanu CA
    Expert Opin Pharmacother; 2011 Nov; 12(16):2493-503. PubMed ID: 21967344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor receptor (EGFR)-targeted therapies in esophagogastric cancer.
    Ayyappan S; Prabhakar D; Sharma N
    Anticancer Res; 2013 Oct; 33(10):4139-55. PubMed ID: 24122977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastric Carcinoma at the Era of Targeted Therapies.
    Dreanic J; Dhooge M; Sion E; Brezault C; Chaussade S; Coriat R
    Curr Drug Targets; 2016; 17(15):1818-1826. PubMed ID: 25944013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted therapies in combination with radiotherapy in oesophageal and gastroesophageal carcinoma.
    Cellini F; Valentini V
    Curr Med Chem; 2014; 21(8):990-1004. PubMed ID: 23992321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER2 testing in gastric cancer: An update.
    Abrahao-Machado LF; Scapulatempo-Neto C
    World J Gastroenterol; 2016 May; 22(19):4619-25. PubMed ID: 27217694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
    Shitara K; Xu RH; Ajani JA; Moran D; Guerrero A; Li R; Pavese J; Matsangou M; Bhattacharya P; Ueno Y; Wang X; Shah MA
    Gastric Cancer; 2024 Sep; 27(5):1058-1068. PubMed ID: 38954176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.